TG Therapeutics, Inc. Announces Fourth Quarter and Year-End

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2014 Financial Results and Business Update

NEW YORK, March 11, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX ) today announced its financial results for the fourth quarter and year ended December 31, 2014 and provided recent company developments along with a business outlook for 2015.

"2014 was an exciting and productive year for TG Therapeutics as we continued to aggressively move forward with the development of our lead drug candidates, TG-1101 and TGR-1202. We ended the year on a high note presenting a significant amount of data at the American Society of Hematology meeting. In addition to very encouraging data on the combination of TG-1101 and TGR-1202, we also presented data demonstrating high response rates for the combination of TG-1101 and ibrutinib, data that we believe supports our now on-going Phase 3 trial of that combination being conducted under a Special Protocol Assessment," stated Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer. "With TG-1101 and TGR-1202, we believe we have two drug candidates each with safety and efficacy profiles that are differentiated and uniquely suited for combination therapy, both with other novel agents, but most importantly, together in our proprietary '1303' combination regimen. For 2015, we plan to focus on recruitment into our GENUINE Phase 3 study, as well as our planned first Phase 3 clinical trial of the combination of TG-1101 and TGR-1202, with a longer term vision toward additional combination trials with the goal of continuing to push toward better patient outcomes."

Recent Developments & Highlights

  • Commenced the GENUINE Phase 3 Clinical Trial of TG-1101 in combination with ibrutinib
     
  • Presented updated data from the Phase 2 trial of TG-1101 in combination with ibrutinib at the 56th American Society of Hematology (ASH) Annual Meeting in December, highlights from the presentation included:
    • 95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in GENUINE Phase 3 Clinical trial
       
    • Combination of TG-1101 + ibrutinib was well tolerated with limited Grade 3/4 events
       
  • Presented updated data from the Phase 1 dose escalation trial of TGR-1202 at ASH in December, highlights from the presentation included:
    • 93% of evaluable CLL patients (13/14) treated at therapeutic dose levels achieved a nodal PR, with 50% (7/14) achieving an objective response per iwCLL (Hallek 2008) criteria
       
    • No drug related hepatic toxicity or colitis observed to date with a median time on study of approximately 6 months and some patients on study for over 1.5 years
       
  • Presented preliminary data from Phase 1/2 dose escalation study of TG-1101 in combination with TGR-1202 at ASH in December, highlights from the presentation included:
    • 100% of evaluable CLL/SLL patients (9/9) had nodal reductions, with 6 of 9 patients achieving an objective response per iwCLL (Hallek 2008) criteria and the remaining patients on study awaiting further assessment
       
    • 43% ORR in Diffuse Large B-cell Lymphoma (DLBCL) (3/7), with 2 patients achieving an independently confirmed Complete Response (CR)
       
    • The combination of TG-1101, TGR-1202, and ibrutinib ("Triple Therapy") was safely administered to 5 patients, and no Grade 3 or 4 events were observed
       
    • 2 of the first 3 evaluable patients responded to the Triple Therapy, including an ibrutinib-refractory and rituximab-refractory patient with Follicular Lymphoma
       
  • Entered into a global collaboration to develop and commercialize anti-PD-L1 and anti-GITR antibody research programs in the field of hematologic malignancies

Key Objectives for 2015

  • Aggressively recruit into the GENUINE Phase 3 Clinical Trial of TG-1101 in combination with ibrutinib
  • Commence additional combination Phase 3 clinical trials, particularly for the Company's proprietary "1303" combination of TG-1101 plus TGR-1202 in patients with Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)
  • Launch new triple therapy combination trials in addition to the currently enrolling Phase 1/2 trial of TG-1101 plus TGR-1202 plus ibrutinib 
  • Commence clinical development for the Company's IRAK4 inhibitor program, expected in the second half of 2015
  • Commence clinical development program for the treatment of autoimmune diseases
  • Present updated data on Phase 1 and 2 clinical trials at major hematology/oncology conferences during 2015

Financial Results for the Fourth Quarter and Full Year 2014

At December 31, 2014, the Company had cash, cash equivalents, investment securities, and interest receivable of $78.9 million, as compared to $45.4 million at December 31, 2013.

Pro-forma cash, cash equivalents, investment securities, and interest receivable as of December 31, 2014 are approximately $98.2 million, including $19.3 million of net proceeds from the utilization of the Company's at-the-market ("ATM") sales facility during the first quarter of 2015. 

Our consolidated net loss for the year ended December 31, 2014, excluding non-cash items and a one-time upfront cash milestone payment, was approximately $25.3 million. The consolidated net loss for the year ended December 31, 2014, inclusive of the items above, was $55.8 million, or $1.64 per diluted share, compared to a consolidated net loss of $20.5 million for the year ended December 31, 2013, representing an increase in consolidated net loss of $35.3 million. The increase in consolidated net loss during the year ended December 31, 2014 was primarily the result of $8.1 million of expense ($4.1 million of which was non-cash stock expense) recorded in conjunction with the Company's conversion from a JV agreement to a licensing agreement for TGR-1202, $1.2 million in non-cash stock expense recorded in conjunction with the licensing arrangement for the IRAK4 inhibitors program, and a $15.9 million increase in non-cash compensation expense related to equity incentive grants. Exclusive of the items mentioned above, other research and development expenses for TG-1101 and TGR-1202 increased $7.1 million and $3.8 million, respectively, over the comparable period in 2013.

Our consolidated net loss for the fourth quarter ended December 31, 2014, excluding non-cash items, was approximately $13.8 million, which included approximately $8.9 million of manufacturing and CMC readiness expenses in preparation for Phase 3 clinical trials and commercialization. The consolidated net loss for the fourth quarter ended December 31, 2014, inclusive of non-cash items, was $18.8 million, or $0.48 per diluted share, compared to a consolidated net loss of $5.7 million during the comparable quarter in 2013, representing an increase in consolidated net loss of $13.1 million. The increase in consolidated net loss during the fourth quarter ended December 31, 2014 was primarily the result of other research and development expenses for TG-1101 and TGR-1202 increasing $9.0 million and $0.2 million, respectively, over the comparable period in 2013.   The increase in other research and development expenses related to TG-1101 was primarily the result of increased manufacturing and clinical trial expenses in preparation for the launch of Phase 3 registration programs. Also contributing to the increase in consolidated net loss during the quarter ended December 31, 2014 was a $4.1 million increase in non-cash compensation expense related to equity incentive grants.

The Company will host an investor conference call Thursday, March 12, 2015, at 8:30am ET, to discuss the Company's 2014 financial results and provide a business outlook for 2015.           

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Year-End 2014 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com . An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com , for a period of 30 days after the call.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX - G

TG Therapeutics, Inc.
Selected Consolidated Financial Data
         
Statements of Operations Information (Unaudited):        
  Three Months Ended December 31, Year Ended December 31,
  2014 2013 2014 2013
License revenue $ 38,095 $ 38,095 $ 152,381 $ 152,381
         
Costs and expenses:        
Research and development:        
Noncash stock expense associated with in-licensing agreements  --   --  5,350,094  -- 
Noncash compensation 2,329,270 149,206 8,731,566 1,041,519
Other research and development 12,807,504 3,606,385 26,004,687 12,621,161
Total research and development 15,136,774 3,755,591 40,086,347 13,662,680
         
General and administrative:        
Noncash compensation 2,709,166 797,942 12,373,726 4,161,629
Other general and administrative 913,279 662,728 3,413,400 2,496,461
Total general and administrative 3,622,445 1,460,670 15,787,126 6,658,090
         
Impairment of in-process research and development  -- 2,797,600  -- 2,797,600
         
Total costs and expenses 18,759,219 8,013,861 55,873,473 23,118,370
         
Operating loss  (18,721,124) (7,975,766) (55,721,092) (22,965,989)
         
Other (income) expense:        
Interest income (16,741) (15,768) (55,049) (30,822)
Other income -- (108,894) (95,427) (108,894)
Interest expense 234,787 240,872 930,701 952,888
Change in fair value of notes payable (142,741) (2,428,124) (720,040) (3,300,951)
Total other (income) expense 75,305 (2,311,914) 60,185 (2,487,779)
         
Net loss (18,796,429) (5,663,852) (55,781,277) (20,478,210)
         
Basic and diluted net loss per common share  $ (0.48)  $ (0.19)  $ (1.64)  $ (0.81)
         
Weighted average shares used in computing basic and diluted net loss per common share 38,913,211 29,440,013 34,068,926 25,413,964
     
Balance Sheet Information:    
  December 31, 2014 December 31, 2013*
  (Unaudited)  
Cash, cash equivalents, investment securities and interest receivable $ 78,861,334 $ 45,431,532
Total assets 86,746,890 48,112,390
Accumulated deficit (95,185,280) (39,404,003)
Total equity 80,101,884 40,054,492
     
* Condensed from audited financial statements.    

Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 13

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 46

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
FCC Opens Prison Jamming Door, Raising Execution Stakes

Updated Category News Views 81

A Regulatory Door Finally Moves Five hundred thousand contraband phones is the sort of estimate that makes a rule change hard to shrug off. On November 19, 2026, the Federal Communications Commission adopted its Third Report and Order in GN Docket No. 13-111, allowing RF jamming in state and local correctional facilities for the first time. That is a meaningful break from...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 146

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 162

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading

Top 5 Most Recently Viewed Articles

Champion of Change Award Boosts Educational Futures

Updated Category News Views 24

Changing the Odds: Paramount Unified's New Honor The education world isn't all about books and grades anymore. It's about inspiring passions and igniting possibilities. That's what Think Together is up to with Paramount Unified School District—a partnership that's earned the latter the 2026 Champion of Change Award. And boy, have they earned it. The Foundation of Trust...

Continue Reading
Allegiant Overhauls Service with UNLV Training

Updated Category News Views 213

Allegiant Airlines and UNLV: A Unique Collaboration The world of airline customer service is about to get a shakeup, thanks to a new collaboration between Allegiant Airlines and the University of Nevada, Las Vegas' renowned William F. Harrah College of Hospitality. It's a partnership that aims to bring a new level of service to the skies, guided by some of the best minds...

Continue Reading
Royal LePage Benchmark and Virtuo: A New Era in Real Estate

Updated Category News Views 166

Transforming Real Estate: Royal LePage Benchmark and Virtuo Partnership This exciting partnership marks a significant step forward for one of Alberta's most prominent brokerages, Royal LePage Benchmark, as it teams up with Virtuo, a leader in AI technology. This collaboration aims to empower agents by enhancing their ability to offer seamless and personalized experiences...

Continue Reading
Frazil Soars in Recognition Among Top Utah Companies

Updated Category News Views 216

Frazil Recognized Among Top Companies Frazil, the award-winning frozen beverage company, has recently made headlines as one of the fastest-growing companies within the state. This recognition speaks volumes about the dedication and commitment to excellence that Frazil embodies in its operations and products. Growth and Innovation Frazil's inclusion on the prestigious...

Continue Reading
Celebrating Legal Excellence: James Scott Farrin Attorneys Honored

Updated Category News Views 96

Acknowledgment of Legal Expertise The Law Offices of James Scott Farrin continuously demonstrate a strong commitment to legal excellence, evidenced by the recent recognition of three of their outstanding attorneys in the 'Super Lawyers' 2025 listing. This accolade reaffirms the firm’s dedication to premier legal representation in personal injury law, and highlights the...

Continue Reading